Vincent Hayes

Chargé D'etudes - Study Coordinator at Valerio Therapeutics

Vincent Hayes has been working at Onxeo S.A. since December 2006, where Vincent holds the position of Chargé d'etudes - Study Coordinator. Vincent also has experience working as an Optimization Engineer at Septodont from July 2010 to June 2011. Prior to that, Vincent worked as an Assistant de recherche at Sanofi from January 2005 to October 2006. Vincent received their Ingénieur degree in Techniques pharmaceutique from Conservatoire National des Arts et Métiers, and their BTS degree in Biochimie from ENCPB.

Location

Paris, France

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Valerio Therapeutics

Valerio Therapeutics is a clinical-stage biotechnology company based in France and in the US that develops new cancer drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. The Company focuses on the development of first-in-class compounds from preclinical (translational) research to human clinical proof-of-concept studies. It thus leads its programs to the most value-creating and attractive inflection points for potential partners. The Company's portfolio is based on platON™, Valerio Therapeutic's decoy oligonucleotide platform. PlatON™ is intended to generate new compounds based on an unparalleled DDR decoy mechanism and capitalizing on the expertise the Company has developed on this type of oligonucleotides. The Company's portfolio includes: - AsiDNA™, a first-in-class product interfering with tumor DNA break repair, based on a decoy agonist mechanism, unmatched in the DDR field, which could, among other things, combat tumor resistance. AsiDNA™ is in clinical development in several trials, in combination with PARP inhibitors or in combination with radiation therapy. - A new family of compounds, OX400, positioned as a new-generation PARP agonists that are designed not to induce resistance and to activate the immune response. The first molecule identified, OX401, is currently being optimized in a preclinical phase. The Company is convinced of the significant therapeutic potential of its decoy oligonucleotide technology and the disruptive innovation it represents, which could pave the way for a new paradigm in cancer treatment.


Headquarters

Paris, France

Employees

51-200

Links